Related Experiment Video
Updated: Apr 27, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
In silico studies of medicinal compounds against hepatitis C capsid protein from north India
Shilu Mathew1, Muhammad Faheem2, Govindaraju Archunan3
1Post Graduate Department of Biotechnology, Jamal Mohamed College, Tiruchirappalli, India. ; Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia. ; Department of Animal Science, Bharathidasan University, Tiruchirappalli, India.
Insights
Hepatitis C virus (HCV) capsid core protein is a key target for new antiviral drugs. Four plant-derived compounds, particularly EGCG, show promise in inhibiting HCV by interacting with the core protein, suggesting a new class of antiviral agents.
Area of Science:
- Virology
- Drug Discovery
- Structural Biology
Background:
- Hepatitis C virus (HCV) infection affects over a million people globally, leading to chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC).
- Current treatments for HCV have limitations and side effects, necessitating the development of novel antiviral compounds.
- The HCV capsid core protein is crucial for viral assembly and RNA packaging, making it a prime target for drug development.
Purpose of the Study:
- To predict the 3D structure of the HCV capsid core protein from Northern India.
- To screen phytochemical inhibitors for their potential to disrupt HCV core protein interactions.
- To evaluate the inhibitory activity of selected flavonoids against HCV genotypes prevalent in North India.
Main Methods:
- 3D structure prediction of HCV capsid core protein.
- Screening of four phytochemical inhibitors: epigallocatechin gallate (EGCG), ladanein, naringenin, and silybin.
- Quantitative structure-activity relationship (QSAR) analysis and molecular docking simulations.
Main Results:
- Molecular docking revealed that EGCG exhibited the highest number of hydrogen bond interactions with the modeled capsid proteins, followed by naringenin and silybin.
- QSAR analysis supported the correlation between the inhibitory activity and the selected bioflavonoids.
- The study identified potential structure-based antiviral compounds targeting the HCV virion capsid.
Conclusions:
- The screened bioflavonoids, particularly EGCG, demonstrate significant potential as inhibitors of the HCV capsid core protein.
- These findings suggest a new class of potent antiviral agents for HCV infection.
- Further in vitro and in vivo studies are required to validate the efficacy of these compounds.
Abstract:
Hepatitis viral infection is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Over one million people are estimated to be persistently infected with hepatitis C virus (HCV) worldwide. As capsid core protein is the key element in spreading HCV; hence, it is considered to be the superlative target of antiviral compounds. Novel drug inhibitors of HCV are in need to complement or replace the current treatments such as pegylated interferon's and ribavirin as they are partially booming and beset with various side effects. Our study was conducted to predict 3D structure of capsid core protein of HCV from northern part of India. Core, the capsid protein of HCV, handles the assembly and packaging of HCV RNA genome and is the least variable of all the ten HCV proteins among the six HCV genotypes. Therefore, we screened four phytochemicals inhibitors that are known to disrupt the interactions of core and other HCV proteins such as (a) epigallocatechin gallate (EGCG), (b) ladanein, (c) naringenin, and (d) silybin extracted from medicinal plants; targeted against active site of residues of HCV-genotype 3 (G3) (Q68867) and its subtypes 3b (Q68861) and 3g (Q68865) from north India. To study the inhibitory activity of the recruited flavonoids, we conducted a quantitative structure-activity relationship (QSAR). Furthermore, docking interaction suggests that EGCG showed a maximum number of hydrogen bond (H-bond) interactions with all the three modeled capsid proteins with high interaction energy followed by naringenin and silybin. Thus, our results strongly correlate the inhibitory activity of the selected bioflavonoid. Finally, the dynamic predicted capsid protein molecule of HCV virion provides a general avenue to target structure-based antiviral compounds that support the hypothesis that the screened inhibitors for viral capsid might constitute new class of potent agents but further confirmation is necessary using in vitro and in vivo studies.
More Related Videos
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis

